期刊文献+

乳腺癌超声造影特征与C-erbB-2、p53表达的相关性研究 被引量:7

Relationship between contrast-enhanced ultrasound features and expression of C-erbB-2 and p53 in breast cancer
下载PDF
导出
摘要 目的 探讨乳腺癌肿块超声造影灌注特征与癌基因C-erbB-2、p53表达的相关性。方法 回顾性分析51例经手术及病理确诊的乳腺癌患者术前超声造影资料,术后对肿瘤标本采用免疫组织学方法测定C-erbB-2、p53蛋白表达情况,并分析其与超声造影特点之间的关系。结果 ①乳腺癌患者肿块C-erbB-2、p53阳性表达率分别为45.1%(23/51)和41.2%(21/51)。②51例乳腺癌患者肿块的增强模式均以向心性、快速增强、高增强为主,与C-erbB-2及p53表达无关。③C-erbB-2、p53阳性表达的乳腺癌患者,肿块均出现灌注不均匀的几率增加,两者间有关联(P<0.05),且C-erbB-2阳性表达的乳腺癌患者肿块出现灌注缺损的几率增加,与阴性表达的乳腺癌患者肿块比较差异有统计学意义(P<0.05)。④C-erbB-2、p53阳性表达的乳腺癌患者,肿块出现放射状或穿支血管的几率增加,两者间有关联(P<0.05),尤其以后者较为显著(P<0.01)。结论 乳腺癌超声造影特征与C-erbB-2、p53阳性表达之间存在一定的相关性。乳腺癌超声造影特征能在一定程度上反映癌细胞的生物学行为及预后,可为临床选择合理的治疗方案提供参考。 ABSTRACT Objective To explore relationship between contrast-enhanced ultrasound features and the expression of C- erbB-2 and p53 in breast cancer. Methods The contrast-enhanced ultrasound appearances of 51 patients with breast cancer confirmed by pathology were analyzed retrospectively. Immunohistochemical method was used to detect the expression of C-erbB-2 and p53 in all the breast cancer. The relationship between contrast-enhanced ultrasound appearances and the expression of C- erbB-2 and p53 was analyzed. Results (1)The positive expression rate of C-erbB-2 and p53 in breast cancer were 45.1% (23/51 ) and 41.2% (21/51 ), respectively. (2)The main enhanced pattern of breast cancer was central, high-speed and high-enhanced, which was not related to C-erbB-2 and p53 (/9〉0.05). (3)The appeared rate of non-uniform perfusion increased in breast cancer with C-erbB-2 and p53 positive expression, and there was a correlation between the two(P〈0.05 ). The appeared rate of perfusion defect increased in breast cancer with C-erbB-2 positive expression. There was a significant difference compared with breast cancer with C-erbB-2 negative expression (P〈0.05). (4)The appeared rate of peripheral radial or perforator vessel increased in breast cancer with C-erbB-2 and p53 positive expression, and there was a correlation between the two (P〈0.05). In particular, the latter was more significant(P〈0.01 ). Conclusion Contrast-enhanced ultrasound features were related to the expression of C- erbB-2 and p53 in breast cancer in some extent. Contrast-enhanced ultrasound features of breast cancer can reflect the biological behavior and prognosis of breast cancer cells, which can provide a reference information for selecting reasonable therapy method in patients with breast cancer.
出处 《临床超声医学杂志》 2012年第9期585-588,共4页 Journal of Clinical Ultrasound in Medicine
基金 广东省科技厅计划项目经费资助(2010B080702007)
关键词 乳腺肿瘤 超声造影 癌基因表达 C-ERBB-2 P53 Breast cancer Contrast-enhanced ultrasound Cancer gene expression C-erbB-2 p53
  • 相关文献

参考文献13

  • 1Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer, 2000,36(8):976-982. 被引量:1
  • 2Linjawi A, Kontogiannea M, Halwani F, et al. Prognostic significanceof p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg, 2004,198( 1 ) : 83-90. 被引量:1
  • 3黄宝俊,徐惠绵,李凯,王怀宇,张昊,田大彤.联合检测多基因在乳腺癌组织中的表达及其临床意义[J].中国普通外科杂志,2005,14(4):247-252. 被引量:11
  • 4Foster FS, Burns PN, Simpson DH, et al. Ultrasound for the visualization and quantification of tumor mierocirculation.Cancer Metastasis Rev, 2000,19(1-2) : 131-138. 被引量:1
  • 5Zdemir A, Kilic K, Ozdemir H, et al. Contrast-enhanced power Doppler sonography in breast lesions: effect on differential diagnosis after mammography and gray scale sonography. J Ultrasound Med, 2004,23(2) : 183-195,. 被引量:1
  • 6Jung EM, Jungius KP, Rupp N, et al. Contrast enhanced harmonic ultrasound for differentiating breast tumors-first results. Clin Hemorheol Microcirc, 2005,33 ( 2 ) : 109-120. 被引量:1
  • 7Schroeder RJ, Bostanjoglo M, Rademaker J, et al. Role of power Doppler techniques and ultrasound contrast enhancement in the differential diagnosis of focal breast lesions. Eur Radiol, 2003,13 ( 1 ) : 68-79. 被引量:1
  • 8Sehgal CM, Arger PH, Rowling SE, et al. Quantitative vascularity of breast masses by Doppler imaging: regional variations and diagnostic impllcations. J Ultrasound Med, 2000,19 (7) : 427-440. 被引量:1
  • 9Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med,2001,7(9) :987-989. 被引量:1
  • 10Mohammed RA, Ellis IO, Lee AH, et al. Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms. Histopathology, 2009,55 ( 1 ) : 1-9. 被引量:1

二级参考文献13

  • 1Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting [ J ]. Clin Cancer Res, 2001 , 7(6) :1577 - 1581. 被引量:1
  • 2Sjostrom J, Collan J, yon Boguslawski K, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer [ J ].Eur J Cancer, 2002, 38 (4) :535 - 542. 被引量:1
  • 3Kim R, Tanabe K, Uehida Y, et al. The role of HER-2 oneoprotein in drug-sensitivity in breast cancer ( review ) [ J]. Oncol Rep, 2002, 9( 1 ) :3 -9. 被引量:1
  • 4Linn SC, Honkoop AH, Hoekman K, et al. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer [ J ]. Br J Cancer, 1996, 74(1) :63 -68. 被引量:1
  • 5Konecny G, Untch M, Arboleda J, et al. Her-2/neu and Urokinase-type plasminogen activator andits inhibitor in breast cancer[ J ]. Clin Cancer Res, 2001 , 7 ( 8 ) , 2448 -2457. 被引量:1
  • 6Chung YL, Sheu ML, Yang SC, et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast caneer[ J]. Int J Cancer. 2002 , 97(3) :306 - 312. 被引量:1
  • 7Yamashita H, Nishio M, Toyama T, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer [ J ] . Breast Cancer Res, 2004, 6( 1 ) :R24 - 30. 被引量:1
  • 8Trock B J, Leonessa F, Clarke R. Muhidrug resistance in breast cancer : a meta- analysis of MDR 1/pg 170 expression and its possible functional significance [ J ]. J Natl Cancer Inst, 1997, 89(13) :917 -931. 被引量:1
  • 9Nakopoulou LL, Alexiadou A, Gorge E, et al. Prognostic significance of the co- expression of p5 3 and c- erbB-2 proteins in breast cancer [ J ]. J Pathol, 1996, 179 ( 1 ) , 31 -38. 被引量:1
  • 10Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance ( MDR 1 ) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin[ J] . Clin Cancer Res,1998, 4 (2) :389-398. 被引量:1

共引文献10

同被引文献74

  • 1曹小丽,刘瑞华,刘美娟,曹立萍,王丽红,张玉莲.乳腺癌患者超声造影表现及其与微血管密度的关系[J].中华医学超声杂志(电子版),2013,10(7):590-595. 被引量:14
  • 2曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 3Steven S. Coughlin and Yasmin Cypel. Epidemiology of Breast Cancer in Women. Breast Cancer Metastasis and Drug Resist- [2013-08-20]. http://link, springer, corn/chapter/10. 1007/978-1-4614-5647-6_2. 被引量:1
  • 4Piscaglia F, Nolsoe C, Dietrich CF, et al. The EFSUMB Guide- lines and Recommendations on the Clinical Practice of ContrastEnhanced Ultrasound (CEUS): Update 2011 on non-hepatic ap- plications. Uhraschall Med, 2012,33(1) : 33-59. 被引量:1
  • 5Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub- types--dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011,22(8): 1736-1747. 被引量:1
  • 6Hudis CA, Gianni L. Triple-negative breast cancer: An unmet medical need. Oncologlst, 2011,16(Suppl 1) :1-11. 被引量:1
  • 7Choi J, Kim do H, Jung WH, et al. Differential expression of immune-related markers in breast cancer by molecular pheno types. Breast Cancer Res Treat, 2013,137(2):417-429. 被引量:1
  • 8Calil LN, lgansi CN, Meurer L, et al. Chlamydia trachomatis and human papillomavirus coinfeetion: Association with pl6INK4a and Ki67 expression in biopsies of patients with pre- neoplastic and neoplastic lesions. Braz J Infect Dis, 2011,15(2): 126-131. 被引量:1
  • 9Suzuki N, Shiota T, Watanabe F, et at. Discovery of novel 5- alkynyl-4-anilinopyrimidines as potent, orally active dual inhibi- tors of EGFR and Her 2 tyrosine kinases. Bioorg Med Chem Lett, 2012,22(1):456 460. 被引量:1
  • 10Kim MY, Choi N. Mammographic and uhrasonographic features of triple-negative breast cancer: A comparison with other breast cancer subtypes. Acta Radiol, 2013,54(8) :889 894. 被引量:1

引证文献7

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部